Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

BioMarin Pharmaceutical Inc. develops and commercializes therapeutic enzyme products. The Company has applied its proprietary enzyme technology to develop products for lysosomal storage diseases and for the treatment of serious burns. BioMarin Pharmaceutical through its subsidiaries provides analytical and diagnostic products and services in the area of carbohydrate biology.
Website: biomarin.com



Growth: Good revenue growth rate 20.1%, there is acceleration compared to average historical growth rates 9.7%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +10.5%. On average the margin is improving unsteadily. Gross margin is high, +79.0%. In the last quarter the company beat the estimated EPS, +50.0%. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.13 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -1.3% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 22.2% higher than minimum and 25.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.7x by EV / Sales multiple , the company can be 58.3% overvalued

Insiders: For the last 3 months insiders sold company shares on $3.3 mln (-0.020% of cap.)

Key Financials (Download financials)

Ticker: BMRN
Share price, USD:  (-1.4%)87.34
year average price 90.33  


year start price 97.24 2023-03-31

max close price 100.30 2023-04-17

min close price 76.22 2023-11-06

current price 87.34 2024-03-29
Common stocks: 188 479 000

Dividend Yield:  0.0%
FCF Yield LTM: -1.3%
EV / LTM EBITDA: 60.6x
EV / EBITDA annualized: 98.6x
Last revenue growth (y/y):  20.1%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  9.7%
Historical growth of EBITDA:  ---
EV / Sales: 6.4x
Margin (EBITDA LTM / Revenue): 10.5%
Fundamental value created in LTM:
Market Cap ($m): 16 462
Net Debt ($m): -1 074
EV (Enterprise Value): 15 388
Price to Book: 3.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-03-15Finbold

Miracle growth: Discover the biotech stock behind decades of jaw-dropping returns

2024-02-26Reuters

BioMarin Pharma gets DOJ subpoena on certain drug testing programs

2024-02-22Seeking Alpha

BioMarin Pharmaceutical, Inc. (BMRN) Q4 2023 Earnings Call Transcript

2024-02-22Zacks Investment Research

Here's What Key Metrics Tell Us About BioMarin (BMRN) Q4 Earnings

2024-02-22Zacks Investment Research

BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates

2024-02-15Zacks Investment Research

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

2024-01-24Zacks Investment Research

Here's Why Investors May Bet on BioMarin (BMRN) Stock Now

2024-01-15Zacks Investment Research

BioMarin Pharmaceutical (BMRN) is a Top-Ranked Growth Stock: Should You Buy?

2024-01-10InvestorPlace

If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names

2023-12-20Reuters

BioMarin settles with Elliott, adds 3 independent directors
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BMRN BMRN BMRN BMRN BMRN BMRN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-26 2023-11-02 2023-08-02 2023-04-28 2023-02-27 2022-10-28
acceptedDate 2024-02-26 13:34:15 2023-11-02 14:53:00 2023-08-02 12:48:35 2023-04-28 13:23:34 2023-02-27 17:25:52 2022-10-28 13:44:57
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
revenue 646M 586M 595M 596M 538M 505M
costOfRevenue 135M 140M 128M 127M 127M 116M
grossProfit 511M 446M 467M 470M 410M 389M
grossProfitRatio 0.790 0.760 0.785 0.788 0.763 0.770
researchAndDevelopmentExpenses 206M 191M 177M 172M 173M 158M
generalAndAdministrativeExpenses 142M 102M 100M 105M 121M 106M
sellingAndMarketingExpenses 133M 122M 116M 118M 125M 111M
sellingGeneralAndAdministrativeExpenses 275M 231M 215M 223M 246M 217M
otherExpenses -15M 4M 3M 16M 16M 16M
operatingExpenses 497M 423M 408M 411M 435M 391M
costAndExpenses 632M 563M 536M 537M 562M 507M
interestIncome 18M 16M 13M 12M 9M 5M
interestExpense 6M 4M 4M 4M 4M 5M
depreciationAndAmortization 27M 26M 25M 28M 25M 25M
ebitda 41M 49M 100M 87M 11M 28M
ebitdaratio 0.064 0.083 0.168 0.146 0.020 0.055
operatingIncome 14M 23M 59M 59M -14M 3M
operatingIncomeRatio 0.022 0.039 0.099 0.100 -0.026 0.005
totalOtherIncomeExpensesNet 5M 19M 3M -3M -4M -5M
incomeBeforeTax 19M 42M 71M 57M -18M -2M
incomeBeforeTaxRatio 0.030 0.071 0.119 0.095 -0.033 -0.004
incomeTaxExpense -1M 1M 15M 6M -17M 5M
netIncome 20M 40M 56M 51M -249 000 -7M
netIncomeRatio 0.032 0.069 0.094 0.085 -0.000 -0.013
eps 0.110 0.210 0.300 0.270 -0.001 -0.036
epsdiluted 0.110 0.210 0.290 0.270 -0.001 -0.036
weightedAverageShsOut 188M 188M 188M 187M 186M 186M
weightedAverageShsOutDil 192M 191M 195M 194M 186M 186M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BMRN BMRN BMRN BMRN BMRN BMRN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-26 2023-11-02 2023-08-02 2023-04-28 2023-02-27 2022-10-28
acceptedDate 2024-02-26 13:34:15 2023-11-02 14:53:00 2023-08-02 12:48:35 2023-04-28 13:23:34 2023-02-27 17:25:52 2022-10-28 13:44:57
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 755 127M 785M 694M 580M 725M 762M
shortTermInvestments 319M 340M 477M 572M 567M 512M
cashAndShortTermInvestments 1 074M 1 126M 1 171M 1 152M 1 292M 1 274M
netReceivables 634M 572M 610M 598M 461M 420M
inventory 1 107M 1 032M 976M 919M 894M 839M
otherCurrentAssets 141M 225M 193M 173M 105M 150M
totalCurrentAssets 2 956M 2 955M 2 950M 2 842M 2 751M 2 683M
propertyPlantEquipmentNet 1 066M 1 067M 1 067M 1 068M 1 073M 1 052M
goodwill 196M 196M 196M 196M 196M 196M
intangibleAssets 295M 302M 310M 326M 339M 354M
goodwillAndIntangibleAssets 491M 499M 507M 522M 535M 550M
longTermInvestments 611M 548M 386M 341M 334M 372M
taxAssets 1 546M 1 524M 1 509M 1 511M 1 505M 1 455M
otherNonCurrentAssets 172M 165M 144M 150M 176M 152M
totalNonCurrentAssets 3 886M 3 803M 3 613M 3 592M 3 624M 3 581M
otherAssets 0 0 0 0 0 0
totalAssets 6 842M 6 758M 6 563M 6 434M 6 375M 6 264M
accountPayables 683M 301M 278M 265M 231M 207M
shortTermDebt 494M 493M 8M 9M 10M 9M
taxPayables 3M 11M 18M 22M 16M 8M
deferredRevenue -1 742M -301M -286M 0 711 000 415 000
otherCurrentLiabilities 683M 670M 597M 324M 347M 304M
totalCurrentLiabilities 118M 1 163M 597M 598M 589M 521M
longTermDebt 593M 593M 1 085M 1 084M 1 083M 1 082M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 120M 105M 98M 92M 100M 958M
totalNonCurrentLiabilities 713M 698M 1 183M 1 176M 1 183M 1 175M
otherLiabilities 1 059M 0 0 0 0 0
capitalLeaseObligations 38M 9M 8M 9M 10M 9M
totalLiabilities 1 890M 1 861M 1 780M 1 775M 1 772M 1 696M
preferredStock 0 0 0 0 0 0
commonStock 189 000 188 000 188 000 188 000 186 000 186 000
retainedEarnings -622M -642M -682M -738M -789M -789M
accumulatedOtherComprehensiveIncomeLoss -29M 6M -19M -11M -4M 31M
othertotalStockholdersEquity 5 602M 5 532M 5 484M 5 408M 5 396M 5 327M
totalStockholdersEquity 4 952M 4 897M 4 783M 4 659M 4 603M 4 569M
totalEquity 4 952M 4 897M 4 783M 4 659M 4 603M 4 569M
totalLiabilitiesAndStockholdersEquity 6 842M 6 758M 6 563M 6 434M 6 375M 6 264M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 6 842M 6 758M 6 563M 6 434M 6 375M 6 264M
totalInvestments 930M 888M 862M 913M 901M 885M
totalDebt 1 087M 1 086M 1 085M 1 084M 1 083M 1 091M
netDebt -754 040M 301M 391M 504M 358M 330M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BMRN BMRN BMRN BMRN BMRN BMRN
reportedCurrency USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-02-26 2023-11-02 2023-08-02 2023-04-28 2023-02-27 2022-10-28
acceptedDate 2024-02-26 13:34:15 2023-11-02 14:53:00 2023-08-02 12:48:35 2023-04-28 13:23:34 2023-02-27 17:25:52 2022-10-28 13:44:57
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000
period Q4 Q3 Q2 Q1 Q4 Q3
netIncome 20M 40M 56M 51M -249 000 -7M
depreciationAndAmortization 27M 26M 25M 26M 25M 25M
deferredIncomeTax -25M -15M 1M -6M -51M -4M
stockBasedCompensation 55M 48M 50M 54M 47M 55M
changeInWorkingCapital -97M 40M -63M -217M -13M 92M
accountsReceivables -58M 14M -7M -139M -28M 39M
inventory -59M -41M -42M -14M -41M -26M
accountsPayables 13M 81M 7M -32M 61M 74M
otherWorkingCapital 8M -14M -20M -32M -5M 5M
otherNonCashItems 47M -4M -111 000 18M 236 000 -2M
netCashProvidedByOperatingActivities 27M 136M 70M -74M 7M 158M
investmentsInPropertyPlantAndEquipment -37M -23M -23M -25M -36M -36M
acquisitionsNet 0 24M 1M 310 000 0 0
purchasesOfInvestments -141M -283M -224M -220M -154M -153M
salesMaturitiesOfInvestments 113M 261M 276M 215M 143M 166M
otherInvestingActivites 1.000 -24M -1M -310 000 -7M 0
netCashUsedForInvestingActivites -65M -46M 30M -30M -55M -23M
debtRepayment -45 000 -606 000 -621 000 -1M -970 000 -513 000
commonStockIssued 15M 4M 0 0 0 0
commonStockRepurchased 0 -5M 0 0 0 0
dividendsPaid 0 -5M 0 0 0 0
otherFinancingActivites -4M 5M 13M -40M 12M 8M
netCashUsedProvidedByFinancingActivities 11M -788 000 12M -41M 11M 8M
effectOfForexChangesOnCash 47M 2M 3M 229 000 71 000 -747 000
netChangeInCash -30M 91M 114M -144M -37M 142M
cashAtEndOfPeriod 755M 785M 694M 580M 725M 762M
cashAtBeginningOfPeriod 785M 694M 580M 725M 762M 620M
operatingCashFlow 27M 136M 70M -74M 7M 158M
capitalExpenditure -37M -23M -23M -25M -36M -36M
freeCashFlow -9M 112M 47M -99M -30M 122M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-07-31 ET (fiscal 2023 q2)
2023 q1
2023-04-26 ET (fiscal 2023 q1)
2022 q4
2023-02-27 ET (fiscal 2022 q4)
2022 q3
2022-10-26 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-04-27 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-22 21:03 ET
BioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
2024-02-08 13:00 ET
BioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
2024-02-06 13:30 ET
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
2024-01-03 13:00 ET
BioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
2023-12-20 21:05 ET
BioMarin Announces Governance Enhancements and Value Creation Initiatives
2023-11-28 13:30 ET
BioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
2023-11-01 20:05 ET
BioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
2023-11-01 20:02 ET
BioMarin Announces Retirement of Jean-Jacques Bienaimé; Appoints Alexander Hardy President and Chief Executive Officer
2023-10-20 20:05 ET
U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia
2023-10-17 12:30 ET
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
2023-09-21 14:00 ET
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
2023-09-15 13:29 ET
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
2023-09-11 12:30 ET
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
2023-09-06 12:30 ET
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
2023-09-05 12:30 ET
BioMarin to Participate in Three Upcoming Investor Conferences
2023-08-30 20:05 ET
BioMarin Announces First Person Treated Commercially with ROCTAVIAN® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
2023-07-31 20:03 ET
BioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
2023-07-12 13:27 ET
BioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET
2023-06-29 18:34 ET
U.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A
2023-06-22 12:00 ET
BioMarin to Present ROCTAVIAN™ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress
2023-05-04 20:01 ET
BioMarin to Participate in Bank of America 2023 Health Care Conference
2023-04-26 20:03 ET
BioMarin Announces Record Breaking First Quarter 2023 Results, Including 15% Year-over-year Growth of Total Revenues
2023-04-13 12:30 ET
BioMarin to Host First Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, April 26, at 4:30pm ET
2023-03-14 12:00 ET
BioMarin to Share Updated Data at 2023 American College of Medical Genetics and Genomics (ACMG) Meeting Demonstrating Commitment to Understanding Long-Term Benefit of VOXZOGO® in Children with Achondroplasia
2023-03-07 21:05 ET
FDA Accepts BioMarin's Supplemental New Drug Application to Expand Use of VOXZOGO® (vosoritide) for Injection to Treat Children with Achondroplasia Under the Age of 5
2023-03-07 00:28 ET
BioMarin Provides Update on FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) Gene Therapy for Adults with Severe Hemophilia A
2023-03-02 13:30 ET
BioMarin to Participate in Three Investor Conferences in March
2023-02-27 21:03 ET
BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
2023-02-14 13:30 ET
BioMarin to Participate Virtually at SVB Securities Global Biopharma Conference on February 16, 2023
2023-02-07 13:00 ET
BioMarin to Host Fourth Quarter and Full-Year 2022 Financial Results Conference Call and Webcast on Monday, February 27, at 4:30 p.m. ET
2023-01-08 16:00 ET
BioMarin Announces Stable and Durable Annualized Bleed Control for ROCTAVIAN™ in Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at 3-Year Analysis
2023-01-04 13:30 ET
BioMarin to Present at 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, at 10:30 am PT /1:30 pm ET, in San Francisco, CA
2023-01-03 21:05 ET
European Medicines Agency Validates Application for Extension of Indication for VOXZOGO® (vosoritide) for injection to Treat Children with Achondroplasia Under the Age of 2
2022-11-23 13:29 ET
BioMarin Announces Advancements in FDA Review of ROCTAVIAN™ (Valoctocogene Roxaparvovec) for Adults with Severe Hemophilia A
2022-11-07 21:30 ET
BioMarin Announces Incremental Progress on Biologics License Application (BLA) Review for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A Program
2022-11-03 12:30 ET
BioMarin to Participate in Two Upcoming Investor Conferences
2022-10-26 20:03 ET
BioMarin Announces Third Quarter 2022 Year-over-Year Total Revenue Growth of 24% (31% Excluding KUVAN®)
2022-10-12 20:05 ET
FDA Accepts BioMarin's Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Adults with Severe Hemophilia A
2022-10-06 23:00 ET
BioMarin Simplifies Organizational Structure to Increase Efficiency
2022-10-04 12:30 ET
BioMarin to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, October 26, at 4:30pm ET
2022-09-29 20:04 ET
BioMarin Resubmits Biologics License Application (BLA) for Valoctocogene Roxaparvovec AAV Gene Therapy for Severe Hemophilia A to the FDA
2022-09-15 12:31 ET
BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report
2022-08-24 20:36 ET
First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)
2022-08-03 20:03 ET
BioMarin Announces Record Revenues in Second Quarter 2022; Increases Full-year 2022 Top and Bottom-line Guidance
2022-07-20 17:49 ET
BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET
2022-07-11 12:31 ET
BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Including 4 Oral and 2 Poster Presentations
2022-06-24 11:15 ET
BioMarin Receives Positive CHMP Opinion in Europe for Valoctocogene Roxaparvovec Gene Therapy to Treat Adults with Severe Hemophilia A
2022-06-21 20:02 ET
BioMarin Announces the Ministry of Health, Labor and Welfare (MHLW) in Japan Granted Approval for VOXZOGO® (vosoritide) for Injection for the Treatment of Children with Achondroplasia, Whose Growth Plates are Not Closed
2022-06-13 16:31 ET
BioMarin Announces Favorable Results from Global Phase 2 Study of VOXZOGO™ (vosoritide) for Injection in Infants and Young Children with Achondroplasia at The Endocrine Society Annual Meeting, ENDO 2022 (June 11-14), in Atlanta
2022-05-31 12:31 ET
BioMarin Announces Durable Hemostatic Efficacy Maintained Over 6 years in Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
2022-05-05 20:04 ET
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
2022-05-05 12:29 ET
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
2022-05-04 13:00 ET
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET
2022-04-27 20:02 ET
BioMarin Announces Record Revenues in First Quarter 2022
2022-04-13 13:00 ET
BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET
2022-03-17 12:31 ET
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A
2022-02-23 21:03 ET
BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
2022-02-17 21:05 ET
BioMarin Provides Updates on Progress in Gene Therapy Programs
2022-02-16 21:00 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2022-02-10 14:00 ET
BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, February 23 at 4:30pm ET
2022-02-09 13:31 ET
BioMarin Sells Priority Review Voucher for $110 Million
2022-02-04 16:15 ET
BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and Allied Disorders (EAHAD) 2-4 February
2022-02-02 21:04 ET
BioMarin Demonstrates Enduring Commitment to Advancing the Standard of Care in Hemophilia A at 15th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) February 2-4
2022-01-09 20:13 ET
BioMarin Announces Stable and Durable Annualized Bleed Control in the Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A; 134-Participant Study Met All Primary and Secondary Efficacy Endpoints at Two Year Analysis
2022-01-04 11:00 ET
BioMarin to Participate in Two Virtual Investor Conferences in January
2021-12-16 21:05 ET
BioMarin and Skyline Therapeutics Announce Strategic Collaboration to Develop Novel Gene Therapies for Cardiovascular Diseases
2021-12-15 21:05 ET
BioMarin Appoints Former CEO of Celgene Corporation, Mark Alles, to Board of Directors
2021-11-30 13:45 ET
BioMarin to Hold Virtual R&D Day at 11:00am ET Today
2021-11-29 13:30 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2021-11-19 15:42 ET
BioMarin Receives FDA Approval for VOXZOGO™ (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates
2021-11-15 13:30 ET
Entos and BioMarin Enter into Agreement for Product Candidates Incorporating Entos' Fusogenix Drug Delivery Platform
2021-10-27 20:05 ET
BioMarin Announces Third Quarter 2021 Financial Results and Corporate Updates
2021-10-25 12:30 ET
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
2021-10-12 12:30 ET
BioMarin to Host Third Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, October 27 at 4:30pm ET
2021-10-04 12:31 ET
BioMarin Hires Industry Veterans to Fill Key Roles in R&D and Technical Operations
2021-09-06 06:00 ET
U.S. FDA Placed a Clinical Hold on BMN 307 Phearless Phase 1/2 Gene Therapy Study in Adults with PKU Based on Interim Pre-clinical Study Findings
2021-08-27 13:51 ET
European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
2021-08-27 13:01 ET
European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
2021-08-25 12:30 ET
BioMarin to Participate in Three Upcoming Virtual Investor Conferences
2021-07-28 20:03 ET
BioMarin Announces Second Quarter 2021 Financial Results and Corporate Updates
2021-07-21 14:01 ET
BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demon...
2021-07-19 15:00 ET
BioMarin Announces Oral Presentation of Positive One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Con...
2021-07-15 12:31 ET
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
2021-07-14 12:30 ET
BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET
2021-07-02 13:05 ET
BioMarin Announces 12 Presentations at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress
2021-06-28 12:31 ET
BioMarin Resubmits Marketing Authorization Application (MAA) to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
2021-06-25 11:29 ET
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
2021-06-15 12:30 ET
BioMarin to Participate in the Virtual BofA Securities 2021 Napa Biopharma Conference
2021-05-27 12:30 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2021-05-24 12:31 ET
European Medicines Agency Grants BioMarin's Request for Accelerated Assessment of Valoctocogene Roxaparvovec for Treatment of Severe Hemophilia A
2021-05-19 12:31 ET
BioMarin Provides Highlights of 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec with the Longest Duration of Clinical Experience for a Gene Therapy in Hemophilia A
2021-05-18 12:30 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2021-05-12 12:31 ET
BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting
2021-05-03 12:30 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2021-04-29 20:03 ET
BioMarin Announces First Quarter 2021 Financial Results and Corporate Updates
2021-04-28 12:31 ET
Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases
2021-04-15 12:31 ET
BioMarin Announces New and Updated Data at 2021 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting Demonstrating Commitment to Understanding Achondroplasia and Potential Treatment Choice
2021-04-13 12:30 ET
BioMarin to Host First Quarter 2021 Financial Results Conference Call and Webcast on Thursday, April 29 at 4:30pm ET
2021-03-20 15:15 ET
BioMarin Announces Oral Presentation at ENDO2021, the Endocrine Society's Annual Meeting, with Data Demonstrating 2 Years of Treatment Benefit in Children with Achondroplasia Treated with Vosoritide
2021-03-08 13:31 ET
BioMarin Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Valoctocogene Roxaparvovec, Investigational Gene Therapy for Hemophilia A
2021-03-03 13:31 ET
BioMarin Completes Full Enrollment in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia
2021-02-25 21:05 ET
BioMarin Announces Fourth Quarter and Record Full-year 2020 Financial Results and Corporate Updates
2021-02-24 13:30 ET
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
2021-02-18 21:01 ET
BioMarin Appoints Former Goldman Sachs Partner and Life Sciences Executive, Maykin Ho, Ph.D. to Board of Directors
2021-01-28 14:00 ET
BioMarin Earns Top Marks in Human Rights Campaign's 2021 Corporate Equality Index
2021-01-26 13:30 ET
BioMarin to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25 at 4:30pm ET
2021-01-10 23:44 ET
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
2021-01-05 13:30 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2020-12-21 13:29 ET
BioMarin Announces Benefit Maintained for Over Two Years in Children with Achondroplasia Treated with Vosoritide in Phase 3 Extension Study
2020-12-01 13:30 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2020-11-17 13:29 ET
BioMarin and Deep Genomics to Collaborate on Advancing Programs Identified Using Artificial Intelligence
2020-11-12 13:30 ET
BioMarin to Participate in Three Upcoming Virtual Investor Conferences
2020-11-09 13:31 ET
BioMarin Expands Vosoritide Clinical Program
2020-11-05 21:05 ET
BioMarin Announces Third Quarter 2020 Total Revenues of $477 Million
2020-11-04 13:30 ET
BioMarin to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference on November 10 at 12:30pm ET
2020-11-03 01:55 ET
Food and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia
2020-10-22 12:30 ET
BioMarin to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Thursday, November 5 at 4:30pm ET
2020-10-07 12:31 ET
BioMarin, Pioneer in Rare Disease Treatments for Phenylketonuria (PKU), Receives FDA Approval of Label Expansion to Allow Maximum Dose of 60 mg for Palynziq® (pegvaliase-pqpz) Injection for Treatment of Adults with PKU
2020-10-05 12:31 ET
Scientific Luminary and MacArthur Fellowship Winner, Kevin Eggan, Ph.D., Joins BioMarin as Head of Research and Early Development
2020-10-02 12:31 ET
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Receives FDA Fast Track Designation for PKU Investigational Gene Therapy, BMN 307
2020-09-29 12:30 ET
BioMarin to Participate in Upcoming Virtual Investor Conference
2020-09-24 13:07 ET
BioMarin, Pioneer in Phenylketonuria (PKU) and Gene Therapy, Doses First Participant in Global PHEARLESS Phase 1/2 Study of BMN 307 Gene Therapy
2020-09-15 12:30 ET
BioMarin to Participate in Four Upcoming Virtual Investor Conferences
2020-09-11 12:32 ET
BioMarin Announces Presentation of Vosoritide Phase 3 Data in Children with Achondroplasia at the American Society for Bone and Mineral Research 2020 Annual Meeting
2020-09-08 13:01 ET
BioMarin Announces The Lancet Publishes Detailed Vosoritide Phase 3 Data Demonstrating Statistically Significant Increase in Annualized Growth Velocity (AGV) Over 52 Weeks in Children with Achondroplasia
2020-09-08 12:00 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2020-08-20 12:31 ET
BioMarin Submits New Drug Application to U.S. Food and Drug Administration for Vosoritide to Treat Children with Achondroplasia
2020-08-19 12:00 ET
BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-08-13 12:31 ET
European Medicines Agency Validates BioMarin's Marketing Authorization Application for Vosoritide to Treat Children with Achondroplasia
2020-08-10 12:30 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2020-08-04 20:05 ET
BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million
2020-07-23 20:07 ET
BioMarin Submits Marketing Authorization Application to European Medicines Agency for Vosoritide to Treat Children with Achondroplasia
2020-07-21 12:30 ET
BioMarin to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 4 at 4:30pm ET
2020-06-29 20:16 ET
BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFO
2020-06-23 12:30 ET
BioMarin to Participate in the Virtual BofA Securities 2020 Napa Biopharma Conference
2020-06-17 13:20 ET
BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit
2020-06-03 12:30 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2020-05-31 20:01 ET
BioMarin Provides Highlights of 4 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2020-05-19 20:15 ET
BioMarin Announces Closing of Exercise by Initial Purchasers of Option to Purchase an Additional $50 million of 1.25% Senior Subordinated Convertible Notes due 2027
2020-05-12 03:26 ET
BioMarin Announces Pricing of Upsized $550 Million Senior Subordinated Convertible Notes Offering
2020-05-11 11:16 ET
BioMarin Announces Proposed Private Offering of $500 Million of Senior Subordinated Convertible Notes
2020-05-06 12:30 ET
BioMarin to Participate in Two Upcoming Virtual Investor Conferences
2020-05-03 20:01 ET
BioMarin Extends Gene Therapy Leadership with DiNAQOR in a Preclinical Collaboration and License Agreement to Develop Gene Therapies for Rare Genetic Cardiomyopathies
2020-04-29 20:01 ET
BioMarin Announces First Quarter 2020 Total Revenue Growth of 25% to $502 million
2020-04-22 20:30 ET
BioMarin Updates Timing of First Quarter 2020 Financial Results Conference Call and Webcast to Wednesday, April 29 at 4:15pm ET
2020-04-21 12:31 ET
BioMarin Appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations, Effective May 4
2020-04-14 12:30 ET
BioMarin to Host First Quarter 2020 Financial Results Conference Call and Webcast on Thursday, April 30 at 4:30pm ET
2020-04-06 12:31 ET
BioMarin Plans Regulatory Submissions for Marketing Authorization of Vosoritide to Treat Children with Achondroplasia in 3Q 2020 in both US and Europe
2020-03-09 19:10 ET
BioMarin's Brinda Balakrishnan, M.D., Ph.D., Honored with 2020 "40 Under 40" Award from the San Francisco Business Times
2020-02-26 21:05 ET
BioMarin Announces Fourth Quarter and Record Full-year 2019 Financial Results
2020-02-20 21:05 ET
BioMarin's Biologics License Application for Valoctocogene Roxaparvovec Accepted for Priority Review by FDA with Review Action Date of August 21, 2020
2020-02-12 13:30 ET
BioMarin to Participate in Two Upcoming Investor Conferences
2020-02-03 21:30 ET
BioMarin Announces CFO Succession
2020-01-29 13:30 ET
BioMarin to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, February 26 at 4:30pm ET
2020-01-13 13:29 ET
BioMarin, Pioneer in Phenylketonuria, to Begin Clinical Trial with BMN 307 Gene Therapy
2020-01-08 13:30 ET
BioMarin to Participate in Goldman Sachs 12th Annual Healthcare CEOs Unscripted: A View from the Top on January 9, 2020 in New York
2020-01-06 13:30 ET
BioMarin to Present at 38th Annual J.P. Morgan Healthcare Conference in San Francisco
2020-01-02 13:31 ET
BioMarin Announces New England Journal of Medicine Publishes 3 Years of Follow-up Data in Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A
2019-12-16 13:15 ET
BioMarin Announces Positive Final Results from Placebo-Controlled Phase 3 Data in Children with Achondroplasia Treated with Vosoritide
2019-11-21 21:04 ET
BioMarin Submits Marketing Authorization Application to European Medicines Agency for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
2019-11-14 16:01 ET
Poised for Significant Growth and Profitability, BioMarin Shares Company Highlights During R&D Day on November 14th in New York
2019-11-14 13:27 ET
BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study
2019-11-12 13:30 ET
BioMarin to Participate in Jefferies London Healthcare Conference on November 21, 2019
2019-11-06 21:05 ET
BioMarin to Highlight Innovative Development Pipeline at R&D Day on November 14th
2019-10-09 12:31 ET
BioMarin to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Wednesday, October 23 at 4:30pm ET
2019-10-07 12:31 ET
BioMarin Promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer
2019-10-01 12:30 ET
BioMarin to Participate in Jefferies Gene Therapy/Editing Summit on October 8, 2019 in New York
2019-09-09 20:05 ET
BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York
2019-08-28 12:30 ET
BioMarin to Participate in Morgan Stanley 17th Annual Global Healthcare Conference on September 10, 2019 in New York
2019-07-16 12:30 ET
BioMarin to Host Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 1 at 4:30pm ET
2019-07-09 12:31 ET
BioMarin Appoints Pharmaceutical Veteran and Former J & J Executive, Liz McKee Anderson, to Board of Directors
2019-07-08 12:01 ET
BioMarin Plans Regulatory Submissions for Marketing Authorization of Valoctocogene Roxaparvovec to Treat Severe Hemophilia A in 4Q 2019 in both U.S. and Europe
2019-06-26 12:31 ET
BioMarin Announces Acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress in Melbourne, Australia from July 6-10, 2019
2019-06-21 15:30 ET
BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
2019-06-18 12:31 ET
BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia
2019-06-05 12:30 ET
BioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA
2019-06-04 12:30 ET
BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome
2019-05-28 10:55 ET
BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe
2019-05-28 10:50 ET
BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A
2019-05-27 20:00 ET
BioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update
2019-05-06 14:12 ET
European Commission Approves Palynziq® (pegvaliase injection) for Treatment of Phenylketonuria (PKU) in Patients Aged 16 Years or Older
2019-04-17 15:18 ET
Forbes Names BioMarin 4th Best Midsize Employer in America
2019-04-02 12:30 ET
BioMarin to Host First Quarter 2019 Financial Results Conference Call and Webcast on Thursday, April 25 at 4:30pm ET
2019-03-06 13:30 ET
BioMarin to Participate in Cowen and Company 39th Annual Health Care Conference on March 12 in Boston
2019-03-01 12:28 ET
BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older

SEC forms

Show financial reports only

SEC form 10
2024-02-26 00:00 ET
BioMarin Pharmaceutical published news for 2023 q4
SEC form 8
2024-02-22 16:06 ET
BioMarin Pharmaceutical published news for 2023 q4
SEC form 8
2024-02-22 16:06 ET
BioMarin Pharmaceutical reported for 2023 q4
SEC form 10
2023-11-02 14:53 ET
BioMarin Pharmaceutical published news for 2023 q3
SEC form 10
2023-11-02 00:00 ET
BioMarin Pharmaceutical published news for 2023 q3
SEC form 8
2023-11-01 16:09 ET
BioMarin Pharmaceutical reported for 2023 q3
SEC form 10
2023-08-02 00:00 ET
BioMarin Pharmaceutical published news for 2023 q2
SEC form 6
2023-07-31 16:05 ET
BioMarin Pharmaceutical reported for 2023 q2
SEC form 8
2023-07-31 00:00 ET
BioMarin Pharmaceutical published news for 2023 q2
SEC form 6
2023-05-30 16:11 ET
BioMarin Pharmaceutical published news for 2023 q1
SEC form 10
2023-04-28 00:00 ET
BioMarin Pharmaceutical published news for 2023 q1
SEC form 8
2023-04-26 00:00 ET
BioMarin Pharmaceutical published news for 2023 q1
SEC form 10
2023-02-27 00:00 ET
BioMarin Pharmaceutical reported for 2022 q4
SEC form 8
2023-02-27 00:00 ET
BioMarin Pharmaceutical reported for 2022 q4
SEC form 8
2023-01-11 00:00 ET
BioMarin Pharmaceutical published news for 2022 q4
SEC form 10
2022-10-28 00:00 ET
BioMarin Pharmaceutical reported for 2022 q3
SEC form 8
2022-10-26 00:00 ET
BioMarin Pharmaceutical reported for 2022 q3
SEC form 10
2022-08-04 00:00 ET
BioMarin Pharmaceutical reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
BioMarin Pharmaceutical reported for 2022 q2
SEC form 10
2022-04-29 00:00 ET
BioMarin Pharmaceutical reported for 2022 q1
SEC form 8
2022-04-27 00:00 ET
BioMarin Pharmaceutical reported for 2022 q1
SEC form 10
2022-02-25 00:00 ET
BioMarin Pharmaceutical published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
BioMarin Pharmaceutical published news for 2021 q4
SEC form 10
2021-10-29 00:00 ET
BioMarin Pharmaceutical published news for 2021 q3
SEC form 8
2021-10-27 00:00 ET
BioMarin Pharmaceutical published news for 2021 q3
SEC form 10
2021-07-30 00:00 ET
BioMarin Pharmaceutical published news for 2021 q2
SEC form 8
2021-07-28 00:00 ET
BioMarin Pharmaceutical published news for 2021 q2
SEC form 10
2021-04-30 00:00 ET
BioMarin Pharmaceutical published news for 2021 q1
SEC form 8
2021-04-29 00:00 ET
BioMarin Pharmaceutical published news for 2021 q1